Literature DB >> 12715327

Epstein-Barr virus and human herpesvirus 8 coinfection and concomitant extranodal nasal-type NK/T cell lymphoma and Castleman disease: case report.

Claire Larroche1, Félix Agbalika, Hélène Poirel, Antoine Martin, Agnès Gautheret-Dejean, Martine Raphaël, Olivier Lortholary.   

Abstract

We describe a 36-year-old man uninfected with human immunodeficiency virus who had confirmed concurrent infection with Epstein-Barr virus (EBV) and human herpesvirus 8 (HHV-8) and their respective lymphoproliferative manifestations, nasal-type NK/T cell lymphoma and Castleman disease. Antibodies to HHV-8 and EBV DNA were found in plasma and peripheral blood mononuclear cells. An EBV-positive nasal-type NK/T cell lymphoma infiltrated the splenic red pulp, whereas the white pulp contained HHV-8-positive plasmablasts, as found in Castleman disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12715327     DOI: 10.1086/374663

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  3 in total

1.  Noninvasive monitoring of infection and rejection after lung transplantation.

Authors:  Iwijn De Vlaminck; Lance Martin; Michael Kertesz; Kapil Patel; Mark Kowarsky; Calvin Strehl; Garrett Cohen; Helen Luikart; Norma F Neff; Jennifer Okamoto; Mark R Nicolls; David Cornfield; David Weill; Hannah Valantine; Kiran K Khush; Stephen R Quake
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

2.  Discovery of herpesviruses in multi-infected primates using locked nucleic acids (LNA) and a bigenic PCR approach.

Authors:  Sandra Prepens; Karl-Anton Kreuzer; Fabian Leendertz; Andreas Nitsche; Bernhard Ehlers
Journal:  Virol J       Date:  2007-09-06       Impact factor: 4.099

3.  Peripheral T cell lymphoma coexisting with Castleman's disease: A case report and literature review.

Authors:  Shuyan Liu; Yuanwen Wang; Tonglin Hu; Chunli Zhang; Zhiyin Zheng
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.